Int J Med Sci
-
Controlled Clinical Trial
How the duration period of erythropoietin treatment influences the oxidative status of hemodialysis patients.
End-stage renal disease is a state of enhanced oxidative stress (OS) and hemodialysis (HD) and renal anemia further augment this disbalance. Anemia correction with erythropoietin (EPO) may improve oxidative status. However, there is no evidence of time dependent effects of EPO therapy on redox status of HD patients. ⋯ Our results suggest that long term administration of EPO attenuated the lipid peroxidation process and restored the levels of antioxidants.
-
Smokeless tobacco use is common in various parts of the world. In Turkey a type of smokeless tobacco called "Maras powder" is widely used in southeastern region. Smoking is known to have an adverse effect on nitric oxide and cardiovascular risk factors. The aim of this study was to evaluate whether there is difference between the effects of Maras powder and cigarette smoking on the cardiovascular risk factors and nitric oxide levels. ⋯ We conclude that Maras powder has similar adverse effects on nitric oxide level and cardiovascular risk parameters and thereby it appears to be harmful as cigarette smoking.
-
To investigate the expression of glioma-associated oncogene homolog 1(Gli-1) in colon cancer and its association with clinicopathological parameters and postoperative liver metastasis. ⋯ Colon cancer is associated with an upregulation of Gli-1 protein expression in colon tissues. In patients with colon cancer, Gli-1 expression level is closely related to lymph node metastases, T stages and postoperative live metastasis-free survival periods, indicative of a possible role of Gli-1 expression in colon cancer progression.
-
To validate a previously developed prediction model for vaginal birth after cesarean (VBAC) using a Japanese cohort. ⋯ The previously published prediction model for VBAC developed in the USA is also available to Japanese women.
-
Adverse event reports (AERs) submitted to the US Food and Drug Administration (FDA) were reviewed to assess the bleeding complications induced by the administration of antiplatelets and to attempt to determine the rank-order of the association. ⋯ The data strongly suggest the necessity of well-organized clinical studies with respect to antiplatelet-associated bleeding complications.